Brief: Grand Pharmaceutical Clinical Trial Applications Radionuclide-Drug Conjugates Tlx591-Cdx And Tlx250-Cdx Accepted By Nmpa
01/08/2022 11:38
Aug 1 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK :
* CLINICAL TRIAL APPLICATIONS RADIONUCLIDE-DRUG CONJUGATES
TLX591-CDX AND TLX250-CDX ACCEPTED BY NMPA
Further company coverage: 0512.HK
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement